.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

John Heymach, MD, PhD, MD Anderson Cancer Center

Articles

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

May 19th 2023

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.